About the Authors
- Michele L. Markwardt
-
Affiliation Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
- Gert-Jan Kremers
-
Current address: Department of Cell Biology, Erasmus Medical Center, Rotterdam, The Netherlands
Affiliation Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States of America
- Catherine A. Kraft
-
Affiliation Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
- Krishanu Ray
-
Affiliation Center for Fluorescence Spectroscopy and the Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
- Paula J. C. Cranfill
-
Affiliation National High Magnetic Field Laboratory and Department of Biological Science, The Florida State University, Tallahassee, Florida, United States of America
- Korey A. Wilson
-
Affiliation National High Magnetic Field Laboratory and Department of Biological Science, The Florida State University, Tallahassee, Florida, United States of America
- Richard N. Day
-
Affiliation Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
- Rebekka M. Wachter
-
Affiliation Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona United States of America
- Michael W. Davidson
-
Affiliation National High Magnetic Field Laboratory and Department of Biological Science, The Florida State University, Tallahassee, Florida, United States of America
- Megan A. Rizzo
-
* E-mail: mrizz001@umaryland.edu
Affiliation Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
Competing Interests
The mutant CFPs described in this article are the topic of a pending patent application from the University of Maryland, Baltimore titled "Fluorescent Proteins and Uses Thereof" (SN 61/249,712). This patent covers the mutations used to derive mCerulean2 and mCerulean2.N variants that are the precursors to mCerulean3. Although the authors are pursuing commercial licensing and sale of their CFP reagents through companies like Clontech and Life Technologies, this does not alter their acceptance and adherence to the PLoS ONE policy as well as National Institutes of Health (NIH) policy for reagent sharing. All reagents described in the article are freely available upon reasonable request for the purpose of academic, non-commercial research, which will likely include deposition of the plasmids encoding mCerulean3 in a repository such as addgene.org.
Author Contributions
Conceived and designed the experiments: MLM GJK RND RMW MWD MAR. Performed the experiments: MLM GJK CAK KR PJCC KAW RND MWD MAR. Analyzed the data: MLM GJK CAK KR PJCC KAW RND MWD MAR. Contributed reagents/materials/analysis tools: RMW. Wrote the paper: GJK CAK RND RMW MWD MAR.